A new trading day began on Friday, with Editas Medicine Inc (NASDAQ: EDIT) stock price up 7.77% from the previous day of trading, before settling in for the closing price of $2.96. EDIT’s price has ranged from $2.91 to $11.69 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 101.57% over the past five years. Meanwhile, its annual earnings per share averaged -44.70%. With a float of $81.70 million, this company’s outstanding shares have now reached $81.77 million.
Let’s look at the performance matrix of the company that is accounted for 265 employees. In terms of profitability, gross margin is 91.33%, operating margin of -310.11%, and the pretax margin is -288.59%.
Editas Medicine Inc (EDIT) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Editas Medicine Inc is 0.94%, while institutional ownership is 69.62%. The most recent insider transaction that took place on Sep 04 ’24, was worth 1,774. In this transaction EVP, CHIEF MEDICAL OFFICER of this company sold 518 shares at a rate of $3.42, taking the stock ownership to the 133,895 shares. Before that another transaction happened on Sep 04 ’24, when Company’s CEO sold 1,555 for $3.42, making the entire transaction worth $5,325. This insider now owns 313,724 shares in total.
Editas Medicine Inc (EDIT) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -44.70% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.70% during the next five years compared to 2.88% growth over the previous five years of trading.
Editas Medicine Inc (NASDAQ: EDIT) Trading Performance Indicators
Here are Editas Medicine Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.85. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.36, a number that is poised to hit -0.79 in the next quarter and is forecasted to reach -2.75 in one year’s time.
Technical Analysis of Editas Medicine Inc (EDIT)
Editas Medicine Inc (NASDAQ: EDIT) saw its 5-day average volume 2.11 million, a positive change from its year-to-date volume of 1.91 million. As of the previous 9 days, the stock’s Stochastic %D was 20.30%. Additionally, its Average True Range was 0.20.
During the past 100 days, Editas Medicine Inc’s (EDIT) raw stochastic average was set at 8.46%, which indicates a significant decrease from 35.44% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.66% in the past 14 days, which was lower than the 66.24% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.74, while its 200-day Moving Average is $6.00. Nevertheless, the first resistance level for the watch stands at $3.28 in the near term. At $3.37, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.55. If the price goes on to break the first support level at $3.01, it is likely to go to the next support level at $2.83. Assuming the price breaks the second support level, the third support level stands at $2.74.
Editas Medicine Inc (NASDAQ: EDIT) Key Stats
With a market capitalization of 263.11 million, the company has a total of 82,238K Shares Outstanding. Currently, annual sales are 78,120 K while annual income is -153,220 K. The company’s previous quarter sales were 510 K while its latest quarter income was -67,610 K.
